Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Christenfeld, Alan M.
Kirkwood, John M.
Oh, William K.
Funding for this research was provided by:
CPS Companion Diagnostics, Inc.